Status:
TERMINATED
Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients
Lead Sponsor:
Emory University
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Kidney Transplantation
Chronic Kidney Failure
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
The toxicity of calcineurin inhibitors(CNI)is a major factor limiting the success of renal transplantation. This protocol aims to replace the calcineurin inhibitor, tacrolimus, with efalizumab early a...
Detailed Description
Over the last two decades there have been significant improvements in renal transplantation due in large part to the decreasing incidence of acute rejection (down to less than 20% for first renal tran...
Eligibility Criteria
Inclusion
- Primary renal transplant recipients
- recipients of deceased donor or living donor transplant
- Age 18-65 years (inclusive)
- Male or female
- Within 3-9 month window post-transplantation
- No episodes of acute rejection prior to enrollment
- Mild impairment of renal function as defined by a calculated CrCl of 35-50 ml/min/m2
Exclusion
- Subjects with any prior solid organ transplant (including kidney)
- Subjects with a history of panel-reactive antibodies greater than 20% or the development of new anti-HLA antibodies after transplantation and prior to enrollment
- Subjects the Investigator deems to be at a relatively higher risk for acute rejection
- HLA-identical living donor pairs
- Evidence of infection with Hepatitis C (antibody positive or PCR positive), Hepatitis B ( surface antigen positive), HIV
- Subjects with BK or CMV viremia prior to enrollment
- Multiple organ transplant recipients
- Subjects with underlying renal disease of focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, hemolytic-uremic syndrome/thrombocytopenic purpura syndrome (due to risk of rapid disease recurrence in the allograft
- EBV negative recipients
- Women who are pregnant or nursing
- Women of child bearing age unwilling or unable to use an acceptable method to avoid pregnancy for the duration of the study and up to 8 weeks after last injection
- Patients not able to tolerate a dose of at least 500 mg of mycophenolate mofetil twice daily
- Allergy to Iodine
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00472082
Start Date
May 1 2007
End Date
April 1 2009
Last Update
January 27 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University
Atlanta, Georgia, United States, 30322